AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05070715 — intervention group
Intervention type: OTHER
Intervention: Analyzing of microplastic level
Description: Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.
Study NCT05170997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cows' milk
Description: Intervention groups will receive a free 12 week supply of cows' milk equating to a pint a day for study participants. Milk is provided by Lakeland dairies.
Study NCT06145295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile online support group (experiment group)
Description: The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
Study NCT06145295 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: offline support group (control group)
Description: The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
Study NCT05170997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: British Dietetic Association Iodine Fact Sheet.
Description: All participants will receive the British Dietetic Association Iodine fact sheet which discusses the importance of iodine and the dietary sources.
Study NCT05170997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: British Dietetic Association Iodine Fact Sheet.
Description: All participants will receive the British Dietetic Association Iodine fact sheet which discusses the importance of iodine and the dietary sources.
Study NCT04951635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo).
Study NCT04951635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Almonertinib
Description: The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo).
Study NCT06241391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET-CT
Description: Prostate Specific Membrane Antigen PET-CT
Study NCT05023668 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02294799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Group
Description: Grade 1, Nonspecific Mandibular Mobilization
Study NCT06297746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subvastus approach
Description: Subvastus approach
Study NCT06297746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Parapatellar approach
Description: Medial Parapatellar approach
Study NCT05627596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ask-Advise-Refer
Description: All patients will be asked if they smoke, advised to quit, and referred to the state quitline
Study NCT05627596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask-Advise-Refer
Description: All patients will be asked if they smoke, advised to quit, and referred to the state quitline
Study NCT05627596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release
Description: 14 mg transdermal nicotine patch
Study NCT02294799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Nonspecific Mandibular Movement.
Study NCT05627596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: 4mg nicotine lozenge
Study NCT06118684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP395 (Part A and B)
Description: EP395 (test product) oral capsule 125 mg. Part A: Dose: 1 capsule as a single dose on Day 1 and Day 14, total daily dose: 125 mg.~Part B: Dose: 3 capsules once daily on Days 9 to 28, total daily dose: 375 mg.
Study NCT06118684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil (Part A)
Description: Verapamil (CYP3A4/Pgp inhibitor), tablet 40 mg. Part A: Dose: 3 tablets twice daily Days 10 to 18, total daily dose: 240 mg.
Study NCT06118684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam (Part B)
Description: Midazolam (CYP3A4 substrate) oral solution 1 mg/mL. Part B: Dose: 4 mL as a single dose on Day 1 and Day 24, total daily dose: 4 mg.
Study NCT06118684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin (Part B)
Description: Digoxin (Pgp substrate) tablet 0.25 mg. Part B: Dose: 1 tablet as a single dose on Day 1 and Day 24, total daily dose: 0.25 mg.
Study NCT04956809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
Study NCT04956809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
Study NCT06441916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate Capsules 150 mg
Description: Dabigatran Etexilate
Study NCT04571203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined Deceased Donor Kidney and Hematopoietic Cell Transplants
Description: This combined kidney and hematopoietic cell transplants with a conditioning regimen with irradiation and ATG creates an environment of immune-tolerance. This promotes hematopoietic cell engraftment.
Study NCT06441916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Capsules 150 mg
Description: Dabigatran Etexilate
Study NCT05575323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-day SBRT and spinal surgery
Description: SBRT and surgical stabilization with or without decompression within 24 hours
Study NCT05575323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Surgical stabilization with or without decompression followed by cRT or SBRT as soon as the wound is healed sufficiently
Study NCT06399887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: All patients in these groups are taught diaphragmatic breathing, which is the basis for DNS, and are asked to maintain it throughout the exercises. The DNS protocol includes a 5-minute warm-up, 40 minutes of DNS exercises (10 minutes for each of the 4 different body parts) and breathing exercises. The DNS exercises included diaphragmatic breathing, Baby Rock, Roll Over, Lying on the Side, Sitting Down, Sitting Upright, Tripod, Kneeling, Squatting, Prone, and Pull Up (CGU). The focus of the first week is to teach and practice basic DNS exercises.
Study NCT05623800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREM-Kit
Description: The PREM-Kit, which was created based on the Information-Motivation-Behavioral Skills model, is used in a series of HIV education sessions as part of the intervention. Over the course of three sessions, there will be a total of six weeks (one session for every two weeks). Three sub-modules, namely HIV facts and information, motivation for HIV preventive behavior, and behavioral skills for HIV prevention, will be emphasized in each session to the participants via flip chart and health educational videos. Additionally, participants will receive a QR code that gives them access to the PREM-Kit's e-flip chart, which they can see at a later time.
Study NCT06399887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Patients in Group II and Group III will be trained in animated CP using the Aymed Medical Locum Wireless System v.2.69.0.12 device. During CP, 10-second contraction and 30-second relaxation cycles are maintained throughout the animated game. Each session will last approximately 20 minutes. The training protocol will consist of a total of 12 sessions of 20 minutes per week for 3 months.
Study NCT05433571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: Multifocal Toric Contact Lenses manufactured in Senofilcon A (C3) material with UV/HEV filter
Study NCT04697875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FiO2 15%)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Study NCT04697875 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo-ambient air (FiO2 21%)
Description: Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Study NCT06247943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Protective Ventilation Strategy
Description: After 10 minutes of pneumoperitoneum, VT 7 ml/kg was used, PEEP 6 cmH2O, FiO2 was 40%, and plateau pressure \<30 cmH2O was maintained throughout.
Study NCT06247943 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: regular ventilation
Description: VT 9ml /kg without PEEP, FiO2 of 60%
Study NCT05455853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: bilateral transcutaneous tibial nerve stimulation,exercise and advices
Description: • First group they will receive morning bilateral transcutaneous tibial nerve stimulation, for 30 minutes, three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise for 15 minutes three times per week, for 4 weeks and bowel care advices.•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices.~Second group•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices.
Study NCT05941195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: In the cognitive behavioral approach based psychoeducation given to the experimental group patients; Addiction and Its Effects, Increasing and Maintaining Motivation, The Cognitive Model and the Cognitive Model of Addiction, Automatic Thoughts That Increase Impulse to Substance Use, Dysfunctional Beliefs Regarding Substance Use, High Risk Situations and Coping Skills,  The topics of Prevention of Slippage and Recurrence and Problem Solving are included.
Study NCT05988476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 5 day/week, two week, one session stretching exercises consisting of ten repetitions of one minute
Study NCT06362057 — intervention group
Intervention type: OTHER
Intervention: Subperiosteal implant framework
Description: A 3D image of an edentulous maxilla bone will be derived from a computed tomography scan of an adult patient and saved as stl data. The solid geometry of the maxilla, including the cortical and spongious bone, was rebuilt from the stl data into the Digital Imaging and Communications in Medicine (DICOM) format with 3D-Doctor (Able Software Corp., MA, USA).~With the Boolean method, force loading will be achieved between prosthetic parts, subperiosteal implant screws and bone tissues
Study NCT05988476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field Therapy
Description: 5 day/week, two week,two sessions consisting of 180 minutes
Study NCT06363942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFE program (exercise intervention)
Description: Participants will be asked to carry out the SAFE program with the help of a caregiver. Our healthcare professionals will visit them during the first week to explain to them and their caregivers how to perform the exercises correctly while using our website. All exercises will be performed using video capsules available on our website (https://safe-seniors.com/fr). The exercises are divided into 4 levels of difficulty: level 1 (light); level 2 (moderate); level 3 (moderate to vigorous); and level 4 (vigorous). Each level lasts 25 to 30 minutes and includes 5 exercise categories split into 5 videos: warm-up, strength, balance, flexibility, and endurance. The exercise intervention will include 3 sessions per week over 12 weeks.
Study NCT06233513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exp 3 Speaking Task
Description: Participant will sit in front of a computer screen in a quiet room and to produce speech based on what is on the screen. Participant may see real words or nonsense words to read. Investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. This task takes about one hour to complete.
Study NCT04653597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Close monitoring
Description: surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS>8 or responds adequately to a simple order
Study NCT04653597 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal intubation
Description: invasive airway management in order to avoid risk of pulmonary aspiration
Study NCT06208475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercises in the following order: squat, bench press, deadlift. Each exercise consisted of 3 sets with 7 repetitions, using a load of 70% 1RM with 120sec of rest between sets.
Study NCT04990466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IIBR-100
Description: Administration of IIBR-100 vaccine
Study NCT04990466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Administration of a currently-approved vaccine for COVID-19
Study NCT06244758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finerenone 20 MG Oral Tablet
Description: The intervention is administered orally.
Study NCT06244758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention is administered orally.
Study NCT05156021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-VEGF
Description: To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation
Study NCT05688124 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IBI351
Description: IBI351 is administered orally
Study NCT05688124 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Esomeprazole
Description: Esomeprazole is administered orally
Study NCT05167643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enituzumab injection+Abesili tablets+Anastrozole tablets
Description: According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
Study NCT05069857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (anti-PD-1 inhibitor)
Description: The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
Study NCT05069857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib (anti-VEGFR inhibitor)
Description: The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
Study NCT05022329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine
Description: This arm receives Pfizer-BioNTech COVID-19 Vaccine
Study NCT05022329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MODERNA SARS-CoV-2 Vaccine
Description: This arm receives MODERNA SARS-CoV-2 Vaccine
Study NCT05598918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early active mobilization
Description: In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.
Study NCT05598918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early passive mobilization
Description: In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
Study NCT03838302 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal tissue retrieval via a posterior colpotomy
Description: Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
Study NCT03838302 — intervention group
Intervention type: PROCEDURE
Intervention: Transabdominal retrieval via trocar
Description: Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
Study NCT04684446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study
Study NCT04684446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd26-S
Description: Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29
Study NCT05211583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum progesterone levels
Description: In order to show change of serum progesterone levels, serial venous blood sampling will be done and also transvaginal ultrasonography will be performed to show ovulation.
Study NCT04875000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remineralizing agent I application
Description: Application of UltraEZ remineralizing agent to the bleached teeth
Study NCT04875000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remineralizing agent II application
Description: Application of 2.5% arginine solution to the bleached teeth
Study NCT04875000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remineralizing agent III application
Description: Application of 2.5% nano-hydroxyapatite solution to the bleached teeth
Study NCT04726969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 2 mg Oral Tablet
Description: Tablets of 2 mg moxidectin
Study NCT04726969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole
Study NCT04726969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole
Study NCT04726969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3 mg Oral Tablet
Description: Tablets of 3 mg ivermectin
Study NCT05436743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-Y Jelly, Topical Gel soaked packs
Description: Topical Gel used as lubricant
Study NCT05436743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water soaked packs
Description: Water soaked packs for reduction of postoperative sore throat
Study NCT04781751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin injection
Description: Carpal tunnel syndrome sonagraphic injection
Study NCT05863208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial intelligence
Description: ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma
Study NCT05863208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff vision
Description: Endocuff vision (Olympus, UK) is used to help the detection of colon adenoma
Study NCT05863208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition endoscope
Description: High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma
Study NCT05863208 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-definition endoscope
Description: High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma
Study NCT05389904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: Routine care
Description: Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive standard of care.